Dr. Marc Ernstoff

Marc Ernstoff

MD

Specializing In:

Kidney cancer Melanoma

About Me

Biography:

Over the past 30 years, I have focused my clinical research in expanding our understanding of the immunobiology of human cancer and the development of new immune therapies. Our NCI funded clinical trials were aimed at minimizing regulatory and suppressive pathways and enhancing existent tumor-specific immune function.

I did my cancer immunology and immunotherapy training with John M. Kirkwood while at Yale University. I continued to develop my experience and qualifications as a translational immunotherapy clinical scientist while at Yale and the University of Pittsburgh and Pittsburgh Cancer Institute. I was a cadre member of the both CALGB and ECOG melanoma programs and am currently a member of the Alliance Experimental Therapeutics Program.

I am currently the Geisel PI on the Cancer Immunotherapy Trial Network and on the executive council of the Cytokine Working Group. I have published over 200 original research manuscripts in the areas of renal cell cancer, melanoma and immune therapy strategies including cytokine therapies, dendritic cell vaccines, immune checkpoint inhibition, targeted therapies and ex vivo expanded effector cells for adoptive transfer. My laboratory has developed phenotypic, functional and molecular assays which enable us to explore the immune response to disease and therapy. While at the University of Pittsburgh and the Pittsburgh Cancer Institute, I was the Director of the Hematology/Oncology Fellowship Program and PI on a T32 Training award from the NCI. 

Over the years, I have successfully mentored five medical students, ten residents, 39 postdoctoral/fellows, and 18 junior faculty. I was Staff Physician at the Taussig Cancer Institute, Cleveland Clinic Foundation and Director of the Melanoma Program and Professor in the Cleveland Clinic Lerner School of Medicine. In 2016, I assumed the role of Professor and Chair, Department of Medicine, Senior Vice President for Clinical Investigation, The Katherine Anne Gioia Chair of Medicine, Roswell Park Cancer Institute and Professor and Chief of the Section of Oncology at the University of Buffalo.


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Professor
  • The Katherine Anne Gioia Chair of Medicine
  • Chair, Department of Medicine
  • Senior Vice President for Clinical Investigation
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
  • Chief, Hematology & Oncology Department
  • Professor of Medicine

Background

Education and Training:

  • 1978 – MD – New York University School of Medicine, New York, NY

Residency:

  • 1981 – Internal Medicine – Bronx Municipal Medical Center and The Hospital of The Albert Einstein College of Medicine, New York, NY

Fellowship:

  • 1984 – Medical Oncology – Yale University School of Medicine, New Haven, CT

Board Certification:

  • 1989 - Diplomate, Subspecialty of Medical Oncology
  • 1981 - Diplomate, American Board of Internal Medicine
  • 1979 – Diplomate, National Board of Medical Examiners

Professional Memberships:

  • 2000-present - American Society of Clinical Oncology Program Committee
  • 1998-present - International Cytokine Society
  • 2016-present - National Comprehensive Cancer Network
  • 1997-2005 - Member, WHO Melanoma Programme
  • 1997-present - American Society of Clinical Oncology, Melanoma Program Committee
  • 1988-present - Society for Biological Therapy/Society of Immunotherapy of Cancer
  • 1988-present - Clinical Immunology Society
  • 1983-present - International Society of Interferon Research
  • 1983-present - American Society of Clinical Oncology
  • 1983-present - American Association for Cancer Research

Honors & Awards

  • 2017-2018 - Marquis Who’s Who in America for Excellence in Medicine
  • 2012 - Best educator, Hematology/Oncology Fellowship Program Geisel School of Medicine
  • 2012 - O. Ross McIntyre Professor of Medicine
  • 2011 - Team Science Award Society of Immunotherapy of Cancer
  • 2009-present - New Hampshire Magazine Top Doctors Poll
  • 2008-2009 - Who’s Who Among Executives and Professionals, “Honors Edition”
  • 2005-2006 - The United Who’s Who Registry, “Honors Edition”
  • 2005-2006 - Who’s Who in American Education, 7th edition
  • 2000-2014 - distinguished teacher awards for Residency Training, Department of Medicine, Hitchcock Clinic
  • 2012 - Best educator, Hematology/Oncology Fellowship Program Geisel School of Medicine
  • 2012 - O. Ross McIntyre Professor of Medicine
  • 2011 - Team Science Award Society of Immunotherapy of Cancer Society of Immunotherapy for Cancer
  • 2009-present New Hampshire Magazine Top Doctors Poll
  • 2004-2005 - Who’s Who in Science and Engineering, 7th edition
  • 2003-2004 - Who’s Who in Medicine and Healthcare, 4th edition
  • 2004-present - Faculty of 1000 Medicine
  • 1997 - First Steven B. Currier Clinical Oncology Scholar, endowment to support clinical melanoma research
  • 1996-present - The Best Doctors in America
  • 1975 - Bernard Baruch Award, American College of Rehabilitation and Physical Medicine

Research

Research Overview:

• Immunobiology of human cancer and the development of new immune therapies
• Renal cell cancer, melanoma and immune therapy strategies; including cytokine therapies, dendritic cell vaccines, immune checkpoint inhibition, targeted therapies and ex vivo expanded effector cells for adoptive transfer
• Exploring the immune response to disease and therapy


Publications

Full Publications list on PubMed

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P.
Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.
PMID: 30267200

Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment.
La Shu S, Yang Y, Allen CL, Maguire O, Minderman H, Sen A, Ciesielski MJ, Collins KA, Bush PJ, Singh P, Wang X, Morgan M, Qu J, Bankert RB, Whiteside TL, Wu Y, Ernstoff MS.
Sci Rep. 2018 Aug 27;8(1):12905. doi: 10.1038/s41598-018-31323-7.
PMID: 30150674 Free PMC Article
Similar articles
Select item 30134131

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.
Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.
Clin Cancer Res. 2018 Jul 25. doi: 10.1158/1078-0432.CCR-18-0945. [Epub ahead of print]
PMID: 30045932


Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
Gorlov I, Orlow I, Ringelberg C, Hernando E, Ernstoff MS, Cheng C, Her S, Parker JS, Thompson CL, Gerstenblith MR, Berwick M, Amos C.
Melanoma Res. 2018 Oct;28(5):380-389. doi: 10.1097/CMR.0000000000000473.
PMID: 29975213

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid Tumors.
Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS. Clin Cancer Res. 2018 Jul 25. pii: clincanres.0945.2018. doi: 10.1158/1078-0432.CCR-18-0945. [Epub ahead of print] PMID: 30045932

Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
Gorlov I, Orlow I, Ringelberg C, Hernando E, Ernstoff MS, Cheng C, Her S, Parker JS, Thompson CL, Gerstenblith MR, Berwick M, Amos C.
Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000473. [Epub ahead of print]
PMID: 29975213

Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor.
Montano R, Khan N, Hou H, Seigne J, Ernstoff MS, Lewis LD, Eastman A.
Oncotarget. 2017 Jun 28;8(40):67754-67768. doi: 10.18632/oncotarget.18834. eCollection 2017 Sep 15.
PMID: 28978069

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.
J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.
PMID: 29743104